EGFR and non-small cell lung carcinoma: A number of clinical studies have shown that treatment of NSCLC cells with EGFR TKIs can induce increased EGFR/IGF-1R heterodimerization and IGF-1R activation [9, 34], enhancing the downstream PI3K/Akt and Mek/Erk pathways [9].